ArticleJournal of medical biochemistry2025
The role of microrna-346 in prostate cancer progression: Clinical significance and biomarker potential.
Article in Journal of medical biochemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: This study aimed to analyse the expression changes and clinical significance of microRNA-346 (miR-346) in PCa genesis, development, and hormone resistance transition. Methods: Data of the middle-aged and elderly male patients who were treated in Tengzhou Central People's Hospital from January 2017 to December 2023 were collected. The tissues and corresponding preoperative serum of 128 patients with newly diagnosed PCa, 130 patients with benign prostatic hyperplasia (BPH), 120 patients with hormone-sensitive PCa (HSPC), 116 patients with castration-resistant PCa (CRPC), and 150 healthy males of the same age who underwent physical examination in the physical examination centre of our hospital were collected. A quantitative real-time polymerase chain reaction was used to detect the relative expression of miR-346 in the subjects' tissues and serum. GraphPad Prism statistical analysis software was utilised to analyse the expression changes of miR-346 in the occurrence and progression of PCa and its correlation with clinical and pathological features. Results: The expression of miR-346 was significantly lower in PCa patients than in BPH patients and healthy population (P < 0.001), while there was no difference between BPH and healthy population (P= 0.516). Tissue and serum expression were positively correlated (P< 0.001). miR-346 was negatively correlated with tPSA, PHI, clinical stage, and Gleason score in PCa tissue/serum (P< 0.001). Serum miR-346 in CRPC patients was negatively correlated with time to transformation (r= 0 .6 5 7 5 ) and survival (r= 0.5699) (P< 0.001). Serum miR-346 was positively correlated with tPSA and ALP in HSPC and CRPC patients (P< 0.001). Conclusions: Serum miR-346 expression in hormone resistance transition in PCa is gradually increasing, making it a potential biomarker for monitoring PCa progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.